Saturday 17 October 2026
Export KMTS’s income statement to Excel — free account
Kestra Medical Technologies, Ltd.
KMTS Healthcare Medical Instruments & Supplies
Kestra Medical Technologies, Ltd.’s revenue for fiscal 2026 (year ended April 2026) was $95.1 million, up 59.0% from fiscal 2025. In the quarter to July 2026, revenue grew 59.9%, EPS fell 50.0%, free cash flow fell 17.8% and total debt rose 74.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.24
1.44
−5.02%
Follow KMTS
| Apr '24 | Apr '25 | Apr '26 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 1.36 | 3.87 |
P/S ratio |
0.00 | 9.89 | 11.80 |
Altman Z″-Score (non-manufacturers) |
(44.29) | (0.94) | (2.55) |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
P/Operating CF |
(24.13) | (24.59) | (59.97) |
Beneish M-Score |
— | (1.69) | 1.67 |
P/B ratio |
0.00 | 2.88 | 4.32 |
Price to Tangible BV |
0.00 | 2.88 | 4.32 |
EV/Sales |
0.00 | 6.60 | 10.19 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
(3.73) | (5.09) | (11.86) |
EV/FCF |
(3.04) | (3.91) | (8.29) |
Quick Ratio |
0.31 | 6.47 | 4.19 |
Current Ratio |
0.45 | 6.72 | 4.41 |
Net Debt/EBITDA |
(0.47) | 2.03 | 1.24 |
Debt/Assets |
92.57% | 13.90% | 11.90% |
Debt/Equity |
(1.32) | 0.20 | 0.16 |
Asset Turnover |
0.00 | 0.35 | 0.29 |
Operating CF/Net income |
0.72 | 0.62 | 0.62 |
Capex/Depreciation |
(1.00) | (2.49) | (3.36) |
Interest Coverage |
(13.65) | (13.75) | (17.86) |
| 0.00% | 6,352.81% | (56.60%) | |
| 0.00% | (73.83%) | (40.24%) | |
ROIC |
(2,631.90%) | (746.28%) | (79.54%) |
Return on Tangible Assets |
(1,254.09%) | (50.02%) | (56.96%) |
Average Days of Receivables |
26.22 | 49.31 | 55.80 |
Research and Development Expense of Revenue |
55.69% | 26.17% | 20.48% |
Selling, General and Administrative Expense of Revenue |
251.44% | 192.15% | 172.53% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
5.35% | 40.58% | 35.37% |
Graham Net Nets |
(0.15) | 0.28 | 0.11 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(22.29%) | (22.29%) | (11.68%) |
Free Cash Flow Yield |
(35.44%) | (17.06%) | (10.42%) |
Revenue per Share |
1.40 | 2.43 | 1.76 |
Operating CF per Share |
(3.63) | (3.16) | (1.51) |
Capex per Share |
(0.61) | (0.95) | (0.65) |
Free Cash Flow per Share |
(4.25) | (4.10) | (2.16) |
Cash per Share |
0.41 | 9.66 | 3.63 |
Shareholders Equity per Share |
(1.62) | 8.36 | 4.79 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(1.62) | 8.36 | 4.79 |
Free Cash Flow |
(84.46) | (100.92) | (116.94) |
Working Capital |
(18.06) | 217.35 | 171.99 |
Capital Expenditures |
(12.23) | (23.31) | (35.24) |
Net Current Asset Value |
(63.31) | 164.99 | 123.55 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.44 | 0.39 | 0.37 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.47 | 0.27 | 0.18 |
Cash ROIC |
(456.12%) | (20.85%) | (23.45%) |
Accounts Receivable Turnover |
0.00 | 11.87 | 8.41 |
Accounts Payable Turnover |
0.00 | 1.49 | 1.81 |
Inventory Turnover |
0.00 | 0.00 | 0.00 |
Average Days of Payables |
317.67 | 245.63 | 215.35 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 |
Average Receivables |
— | 5.04 | 11.31 |
Average Payables |
— | 23.93 | 25.63 |
Average Assets |
— | 170.85 | 327.10 |
Average Common Equity |
— | (1.99) | 232.53 |
Columns are period end dates · fundamentals updated 2 Oct 2026